Currently, there are 304.62M common shares owned by the public and among those 246.97M shares have been available to trade.
The company’s stock has a 5-day price change of -5.83% and -16.70% over the past three months. IOVA shares are trading 7.38% year to date (YTD), with the 12-month market performance up to 39.46% higher. It has a 12-month low price of $6.00 and touched a high of $18.33 over the same period. IOVA has an average intraday trading volume of 6.31 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -7.73%, -10.90%, and -18.97% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Iovance Biotherapeutics Inc (NASDAQ: IOVA) shares accounts for 68.48% of the company’s 304.62M shares outstanding.
It has a market capitalization of $2.66B and a beta (3y monthly) value of 0.53. The earnings-per-share (ttm) stands at -$1.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.21% over the week and 6.36% over the month.
Earnings per share for the fiscal year are expected to increase by 33.29%, and 34.44% over the next financial year.
Looking at the support for the IOVA, a number of firms have released research notes about the stock. UBS stated their Buy rating for the stock in a research note on October 24, 2024, with the firm’s price target at $17. Piper Sandler coverage for the Iovance Biotherapeutics Inc (IOVA) stock in a research note released on July 29, 2024 offered a Neutral rating with a price target of $10. Goldman was of a view on November 20, 2023 that the stock is Buy, while Barclays gave the stock Overweight rating on September 18, 2023, issuing a price target of $40- $18. Wells Fargo on their part issued Overweight rating on May 30, 2023.
